Revised version available on all devices coming soon!
Development of ACE
The Addenbrooke's Cognitive Examination (ACE) is one of the most popular and commonly used cognitive tests in dementia clinics and in the assessment of other neurological disorders.
ACEmobile is the latest version of the ACE (the ACE-III) with all of the advantages that computerisation offers.
As a clinician, working in dementia clinics, ACEmobile provides a sensitive, reliable, secure and easy to administer clinical tool for you and your team to assess cognition.
ACEmobile has the advantage that it supports staff who are less skilled and experienced to reliably and accurately assess cognition.
Electronic data collection allows ACEmobile to be an easy to use audit and research tool.
Embedded administration instructions mean you no longer need to refer to the administration manual and can relax knowing you, or your team, are using the correct wording and administering the measure accurately and reliably.
Scoring of the ACEmobile has been designed to be automatic and friendly to the clinician. No tallying of scores or reference to scoring guidelines is required. You will no longer need to worry about mental arithmetic.
With one click of a button ACEmobile will
immediately report ACE scores to your iPad screen or email them to you, allowing you to effortlessly print a report for the patient notes.
ACEmobile has been designed to to support your team with automated audit reports.
We aspire for ACEmobile to be freely available to be used as a research tool. This will allow us to develop better normative data for different patient populations and develop ACE sub-test norms.
Why is the ACEmobile free?
Our vision has been to develop a version of the ACE-III that benefits from the advantages of computerised assessment whilst adhering to our philosophy of wanting to create tests for clinicians to use across the world at no cost.
The ACEmobile team are committed to provide a measure that is free for clinical use within a not for profit environment. We perceive a need for clinical assessment to be delivered at a high, reliable standard in all settings and recognise that new technology (such as the iPad) can be served to aid clinicians in the field. We hope to develop ACEmobile towards being increasingly sensitive to early disease onset, and changes experienced by an individual.
We hope that in providing this tool at no cost, there is an incentive for clinicians to engage with the process of improving this measure and so improving their own service into the future.